Literature DB >> 16790781

Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways.

A Grabig1, D Paclik, C Guzy, A Dankof, D C Baumgart, J Erckenbrecht, B Raupach, U Sonnenborn, J Eckert, R R Schumann, B Wiedenmann, A U Dignass, A Sturm.   

Abstract

Toll-like receptors (TLRs) are key components of the innate immune system that trigger antimicrobial host defense responses. The aim of the present study was to analyze the effects of probiotic Escherichia coli Nissle strain 1917 in experimental colitis induced in TLR-2 and TLR-4 knockout mice. Colitis was induced in wild-type (wt), TLR-2 knockout, and TLR-4 knockout mice via administration of 5% dextran sodium sulfate (DSS). Mice were treated with either 0.9% NaCl or 10(7) E. coli Nissle 1917 twice daily, followed by the determination of disease activity, mucosal damage, and cytokine secretion. wt and TLR-2 knockout mice exposed to DSS developed acute colitis, whereas TLR-4 knockout mice developed significantly less inflammation. In wt mice, but not TLR-2 or TLR-4 knockout mice, E. coli Nissle 1917 ameliorated colitis and decreased proinflammatory cytokine secretion. In TLR-2 knockout mice a selective reduction of gamma interferon secretion was observed after E. coli Nissle 1917 treatment. In TLR-4 knockout mice, cytokine secretion was almost undetectable and not modulated by E. coli Nissle 1917, indicating that TLR-4 knockout mice do not develop colitis similar to the wt mice. Coculture of E. coli Nissle 1917 and human T cells increased TLR-2 and TLR-4 protein expression in T cells and increased NF-kappaB activity via TLR-2 and TLR-4. In conclusion, our data provide evidence that E. coli Nissle 1917 ameliorates experimental induced colitis in mice via TLR-2- and TLR-4-dependent pathways.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16790781      PMCID: PMC1489743          DOI: 10.1128/IAI.01449-05

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  71 in total

1.  Failure to induce oral tolerance to a soluble protein in patients with inflammatory bowel disease.

Authors:  Thomas A Kraus; Lisa Toy; Lisa Chan; Joseph Childs; Lloyd Mayer
Journal:  Gastroenterology       Date:  2004-06       Impact factor: 22.682

Review 2.  Inflammatory bowel disease: the role of environmental factors.

Authors:  Silvio Danese; Miquel Sans; Claudio Fiocchi
Journal:  Autoimmun Rev       Date:  2004-07       Impact factor: 9.754

3.  Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis.

Authors:  Seth Rakoff-Nahoum; Justin Paglino; Fatima Eslami-Varzaneh; Stephen Edberg; Ruslan Medzhitov
Journal:  Cell       Date:  2004-07-23       Impact factor: 41.582

4.  Effect of lactobacillus on the gut microflora and barrier function of the rats with abdominal infection.

Authors:  Huan-Long Qin; Tong-Yi Shen; Zhi-Guang Gao; Xiao-Bing Fan; Xiao-Min Hang; Yan-Qun Jiang; Hui-Zhen Zhang
Journal:  World J Gastroenterol       Date:  2005-05-07       Impact factor: 5.742

Review 5.  Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2.

Authors:  E Cario
Journal:  Gut       Date:  2005-04-19       Impact factor: 23.059

6.  Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria.

Authors:  Elizabeth Furrie; Sandra Macfarlane; George Thomson; George T Macfarlane
Journal:  Immunology       Date:  2005-08       Impact factor: 7.397

Review 7.  Toll-like receptors: linking innate and adaptive immunity.

Authors:  Chandrashekhar Pasare; Ruslan Medzhitov
Journal:  Adv Exp Med Biol       Date:  2005       Impact factor: 2.622

8.  Nonpathogenic Escherichia coli strain Nissle1917 prevents murine acute and chronic colitis.

Authors:  Nobuhiko Kamada; Nagamu Inoue; Tadakazu Hisamatsu; Susumu Okamoto; Katsuyoshi Matsuoka; Toshiro Sato; Hiroshi Chinen; Kyong Su Hong; Takaya Yamada; Yumiko Suzuki; Tatsuo Suzuki; Noriaki Watanabe; Kanji Tsuchimoto; Toshifumi Hibi
Journal:  Inflamm Bowel Dis       Date:  2005-05       Impact factor: 5.325

9.  Probiotic therapy in the prevention of pouchitis onset: decreased interleukin-1beta, interleukin-8, and interferon-gamma gene expression.

Authors:  Karen M Lammers; Athanasios Vergopoulos; Nina Babel; Paolo Gionchetti; Fernando Rizzello; Claudia Morselli; Elisabetta Caramelli; Michelangelo Fiorentino; Antonia d'Errico; Hans-Dieter Volk; Massimo Campieri
Journal:  Inflamm Bowel Dis       Date:  2005-05       Impact factor: 5.325

10.  Association between Toll-like receptor 4 and inflammatory bowel disease.

Authors:  Liekele E Oostenbrug; Joost P H Drenth; Dirk J de Jong; Ilja M Nolte; Elvira Oosterom; Hendrik M van Dullemen; Klaas van der Linde; Gerard J te Meerman; Gerrit van der Steege; Jan H Kleibeuker; Peter L M Jansen
Journal:  Inflamm Bowel Dis       Date:  2005-06       Impact factor: 5.325

View more
  70 in total

1.  The angiogenic effect of probiotic Bacillus polyfermenticus on human intestinal microvascular endothelial cells is mediated by IL-8.

Authors:  Eunok Im; Yoon Jeong Choi; Cho Hee Kim; Claudio Fiocchi; Charalabos Pothoulakis; Sang Hoon Rhee
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-11       Impact factor: 4.052

Review 2.  Intestinal effect of the probiotic Escherichia coli strain Nissle 1917 and its OMV.

Authors:  Ava Behrouzi; Hoora Mazaheri; Sarvenaz Falsafi; Zahra Hoseini Tavassol; Arfa Moshiri; Seyed Davar Siadat
Journal:  J Diabetes Metab Disord       Date:  2020-05-01

3.  Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science.

Authors:  Elaine O Petrof
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2009-09-01

Review 4.  Inflammatory bowel disease, past, present and future: lessons from animal models.

Authors:  Atsushi Mizoguchi; Emiko Mizoguchi
Journal:  J Gastroenterol       Date:  2008-02-24       Impact factor: 7.527

Review 5.  Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'.

Authors:  Dimitrios Damaskos; George Kolios
Journal:  Br J Clin Pharmacol       Date:  2008-02-12       Impact factor: 4.335

Review 6.  Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update.

Authors:  Franco Scaldaferri; Viviana Gerardi; Francesca Mangiola; Loris Riccardo Lopetuso; Marco Pizzoferrato; Valentina Petito; Alfredo Papa; Jovana Stojanovic; Andrea Poscia; Giovanni Cammarota; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

7.  Evaluation of anti-colitic effect of lactic acid bacteria in mice by cDNA microarray analysis.

Authors:  Hoyong Lee; Young-Tae Ahn; Jung-Hee Lee; Chul-Sung Huh; Dong-Hyun Kim
Journal:  Inflammation       Date:  2009-12       Impact factor: 4.092

8.  The anticancer effect of probiotic Bacillus polyfermenticus on human colon cancer cells is mediated through ErbB2 and ErbB3 inhibition.

Authors:  Elise L Ma; Yoon Jeong Choi; Jinyoung Choi; Charalabos Pothoulakis; Sang Hoon Rhee; Eunok Im
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

Review 9.  Probiotics in the management of colonic disorders.

Authors:  Eamonn M M Quigley
Journal:  Curr Gastroenterol Rep       Date:  2007-10

Review 10.  Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis.

Authors:  Jacquelyn J Maher; Pablo Leon; James C Ryan
Journal:  Hepatology       Date:  2008-08       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.